Scholar Rock Holding Corporation filings document the public-company record of a Nasdaq-listed biopharmaceutical issuer focused on apitegromab, spinal muscular atrophy, and myostatin biology programs. Current reports on Form 8-K cover operating and financial results, Regulation FD business updates, apitegromab regulatory disclosures, preliminary cash updates, and amendments correcting furnished earnings materials.
The company’s SEC record also includes proxy materials for director elections, auditor ratification, and advisory executive-compensation votes. Capital-structure disclosures identify SRRK common stock listed on the Nasdaq Global Select Market and include shelf registration and at-the-market offering materials for common stock sales.
Scholar Rock Holding Corp saw a large warrant exercise by a 10% owner–affiliated group. On December 11, 2025, a warrant to buy 1,575,008 shares of common stock at $7.35 per share was exercised, eliminating the warrant position.
Following the transaction, entities associated with Invus Global Management, LLC, Siren, L.L.C. and related investment vehicles held 10,825,013 shares of Scholar Rock common stock directly. The filing notes a chain of control from Invus Public Equities, L.P. up through Invus Global Management, Siren, and ultimately to Mr. Raymond Debbane, with standard disclaimers of beneficial ownership among the reporting persons.
Scholar Rock Holding Corp’s chief scientific officer, Mo Qatanani, reported two stock sales on January 22, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. He sold 2,119 shares of common stock at a weighted average price of $45.8655 and another 12,779 shares at a weighted average price of $46.8541, with each sale executed through multiple trades within the stated price ranges. After these transactions, his reported beneficial holdings consist of 85,660 restricted stock units (RSUs), and the earlier figure of 98,439 beneficially owned securities reflected 12,779 shares plus these RSUs before the second sale.
Scholar Rock Holding Corp. filed a Form 144 notice for a planned sale of 14,898 shares of its common stock. The shares are to be sold through J.P. Morgan Securities LLC on Nasdaq, with an aggregate market value of 686,053. The securities were acquired on 01/15/2026 as a restricted stock award from the issuer, with the same date listed for payment and the nature of payment noted as “NA.”
The filing notes that 102,007,457 shares of common stock were outstanding, providing context for the planned sale. It also discloses that a seller named Mohammed Qatanani sold 136,462 common shares for gross proceeds of 6,169,788 on 12/04/2025, and 13,112 common shares for 592,611 on 01/14/2026, over the prior three months.
Scholar Rock Holding Corp's chief scientific officer, Mo Qatanani, reported an automatic sale of company stock related to equity compensation. On January 16, 2026, Qatanani sold 8,406 shares of common stock at an average price of $44.4777 per share. According to the footnotes, this was a mandatory "sell to cover" transaction to satisfy tax withholding obligations arising from the vesting of restricted stock units on January 15, 2026, rather than a discretionary trade.
After this transaction, Qatanani beneficially owned a total of 100,558 equity-based units, consisting of 14,898 shares of common stock and 85,660 restricted stock units that are fully vested.
Scholar Rock Holding Corp’s Chief Human Resources Officer, Caryn Parlavecchio, reported a required tax-related sale of company stock. On January 16, 2026, she sold 6,600 shares of common stock at an average price of $44.4777 per share to cover tax withholding triggered by the vesting of restricted stock units on January 15, 2026. The filing notes this was a mandatory “sell to cover” transaction under the company’s equity incentive plans, not a discretionary trade. After the sale, she beneficially owned 148,864 equity interests, consisting of 78,283 shares of common stock and 70,581 RSUs.
Scholar Rock Holding Corp’s chief medical officer, Jing L. Marantz, sold 5,798 shares of common stock on January 16, 2026 at $44.4777 per share. The filing explains this sale was required to cover tax withholding from the vesting of restricted stock units (RSUs) on January 15, 2026 under the company’s equity incentive plans, and it was not a discretionary trade.
These shares relate to RSU awards granted on February 12, 2024. After the tax-related sale, Marantz beneficially owns 95,687 shares, consisting of 24,974 shares of common stock and 70,713 RSUs. Each RSU is fully vested and represents the right to receive one share of Scholar Rock common stock.
Scholar Rock Holding Corp’s general counsel, Junlin Ho, reported a small insider stock sale tied to restricted stock unit (RSU) vesting. On January 16, 2026, Ho sold 8,016 shares of common stock at an average price of $44.4777 per share.
According to the filing, this sale was mandated under the company’s equity incentive plans solely to cover tax withholding obligations from RSUs that vested on January 15, 2026, and did not represent a discretionary trade. After the transaction, Ho beneficially owned 214,553 equity-linked interests, consisting of 121,471 shares of common stock and 93,082 RSUs, all tied to fully vested awards.
Scholar Rock Holding Corp’s chief scientific officer, Mo Qatanani, reported option exercises and a share sale in company stock. On January 14, 2026, Qatanani exercised several stock options covering a total of 13,112 shares of common stock at exercise prices of $7.62, $10, $15.75, $18.08, and $35.15 per share.
On the same day, Qatanani sold 13,112 shares of common stock at a weighted average price of $45.1961 per share under a Rule 10b5-1 trading plan adopted on March 31, 2025. After these transactions, Qatanani directly holds 108,964 restricted stock units (RSUs) and still has multiple stock options outstanding with unvested portions of 961, 11,250, 47,143, and 32,142 shares, subject to continued service-based vesting.
Scholar Rock Holding Corp's Chief Financial Officer Vikas Sinha reported an automatic sale of common stock linked to equity award vesting. On January 13, 2026, he sold 16,755 shares of Scholar Rock common stock at $42.70 per share in a transaction coded "S".
According to the disclosure, the shares were sold solely to cover tax withholding obligations arising from the vesting of performance- and time-based restricted stock units (PSUs) and did not represent a discretionary trade. The vesting relates to awards granted on April 27, 2025, including 50,000 PSUs that vested on January 12, 2026, with additional PSUs scheduled to vest through April 27, 2029 if service and performance conditions are met. Following the transaction, Sinha's equity position consists of 33,245 shares of common stock, 100,000 restricted stock units, and 450,000 PSUs.
Scholar Rock Holding Corp's Chief Operating Officer, R. Keith Woods, reported a sale of common stock that was executed solely to cover taxes on recently vested performance-based restricted stock units (PSUs). On January 13, 2026, he sold 16,746 shares of common stock at $42.70 per share in a mandated "sell to cover" transaction under the company’s equity incentive plans, rather than a discretionary trade.
These shares relate to PSU awards granted on April 27, 2025, with 50,000 PSU shares vesting on January 12, 2026 and additional tranches scheduled through April 27, 2029 if service and performance conditions are met. After the tax-related sale, Woods has beneficial ownership of 583,254 share-based interests, consisting of 33,254 shares of common stock, 100,000 time-based RSUs and 450,000 PSUs.